León-Toirac E, Camacho F, Sarmiento ME, Alerm A, González D, González H, Acosta A

Language: Spanish
References: 20
Page: 28-35
PDF size: 180.34 Kb.

ABSTRACT

Neisseria meningitidis serogroup B still produces a significant morbidity and mortality. Bacterial capsular polysaccharide in serogroup B shows structural homologies with human proteins and poor immunogenicity which make difficult the development of vaccines and polyclonal and monoclonal antibodies (MAb) against it. Artificial libraries of human antibodies via the expression and selection of them in bacteriophages have become known. Those antibodies are used as specific recognizing molecules capable to join to almost any existing target, with advantages over conventional MAb due to its faster obtainment without needing animal immunization, emerging as an attractive alternative for the production of MAb against complex or particular antigens. This was a basic experimental piece of work, using a phage library that expresses variable regions of human immunoglobulins to identify ligands with the capacity to recognize N. meningitidis serogroup B polysaccharide. Polyclonal ELISA screening suggests the existence of human antibodies expressed in phages which recognized the antigen of interest.

REFERENCES

1. Sotolongo F, Campa C, Casanueva V, Fajardo ME, Cuevas IE, González N. Cuban Meningococcal BC Vaccine: Experiences & Contributions from 20 Years of Application. MEDICC Review 2007;9(1):16-22.

2. Merchán Y, Cuevas M. Estudio de un método de desadsorción de los componentes de VA-MENGOC-BC para el control de calidad por HPLC. VacciMonitor 2003;12(3):1-4.

3. Domínguez F, Menéndez J, Ochoa R. An effective serogroup B meningococcal vaccine. Vaccine 2006;24(49-50):7025-6.

4. Nicolas P. Vaccinal strategies in response to new epidemiological challenges in 2010. Reasonable hope for a "B" meningococcal vaccine. Med Trop 2010;70(4):325-32.

5. Amir-Kroll H, Riveron L, Sarmiento ME, Sierra G, Acosta A, Cohen IR. A conjugate vaccine composed of a heat shock protein 60 T-cell epitope peptide (p458) and Neisseria meningitidis type B capsular polysaccharide. Vaccine 2006;24:6555-63.

6. Beninati C, Arseni S, Mancuso G, Magliani W, Conti S, Midiri A, et al. Protective Immunization against Group B Meningococci Using Anti-Idiotypic Mimics of the Capsular Polysaccharide. The Journal of Immunology 2004;172:2461-8.

7. Krug LM, Ragupathi G, Hood C, George C, Hong F, Shen R, et al. Immunization with N-propionyl polysialic acid-KLH conjugate in patients with small cell lung cancer is safe and induces IgM antibodies reactive with SCLC cells and bactericidal against group B meningococci. Cancer Immunol Immunother 2012;61(1):9-18.

8. Cabezas Sh, Rojas G, Pavón A, Álvarez M, Pupo M, Guillén G, et al. Selection of phage-displayed human antibody fragments on Dengue virus particles captured by a monoclonal antibody: Application to the four serotypes. Journal of Virological Methods 2008;147(2):235-43.

9. BIOTECH. Human single Fold scFv Libraries I + J (Tomlinson I+J) Grade Frac System Farmacia. California, SF., USA: Assay Biotechnology Company, Inc; 2006.

10. Shin JS, Lin JS, Anderson PW, Insel RA, Nahm MH. Monoclonal antibodies specific for Neisseria meningitidis group B polysaccharide and their peptide mimotopes. Infection and Immunity 2001;69(5):3335-42.

11. Svenerholm L. Quantitative estimation of Sialic II. A colorimetric resorcinol hidrochloric acid method. Biochem. Byophy Acta 1957;24:609-13.

12. Lowry O. A protein measurement with the folin - phenol reagent. Biol. Chem 1951;193:265-75.

13. WHO Expert Committee on Biological Standardization. Recommendations to assure the quality, safety and efficacy of group A meningococcal conjugate vaccines. Geneva: WHO; 2006. Disponible en: http://www.who.int/biologicals/ publications/trs/areas/ vaccines/meningococcal/en/index.html.

14. Laemmli UK. Cleaveage of strutural proteins during the assembly of the head of bacteriophage T4. Nature 1970;227:680-5.

15. Tsai CM, Frash SE. Silver stain a method to detection after polyacrylamide gel electrophoresis. Anal Biochem 1982;119:115-9.

16. Balboa JA, Estrada J, Nápoles LD, Aguilar S, González H, Hernández D, et al. Purificación de lipopolisacárido de Neisseria meningitidis a partir de una fracción colateral del proceso de producción de VA-MENGOC-BC®. VacciMonitor 2008; 17(1):17-26.

17. Ochoa R, Nerey M, Martínez JC. Use of Poly-L-lysine Precoating in an ELISA for the Detection of Antibodies against Serogroup C Neisseria meningitidis Capsular Polysaccharide. Biotecnología Aplicada 1999;16(3):173-5.

18. Lo Passo C, Romeo A, Pernice I, Donato P, Midiri A, Mancuso G, et al. Peptide Mimics of the Group B Meningococcal Capsule Induce Bactericidal and Protective Antibodies after Immunization. The Journal of Immunology 2007;178(7):4417- 23.

19. Menéndez T, Santiago-Vispo NF, Cruz-Leal Y, Coizeau E, Garay H, Reyes O, et al. Identification and characterization of phagedisplayed peptide mimetics of Neisseria meningitidis serogroup B capsular polysaccharide. International Journal of Medical Microbiology 2011;301(1):16-25.

20. Krambovitis E, McIllmurray MB, Lock PA, Holzel H, Lifely MR, Moreno C. Murine monoclonal antibodies for detection of antigens and culture identification of Neisseria meningitidis group B and Escherichia coli K-1. J Clin Microbiol 1987;25(9):1641-4.